Skip to content

The effect of Padzahr tablets on the symptoms of COVID-19

The effect of Persian Medicine Formula (Padzahr) on clinical manifestations of patients with COVID-19

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20131129015584N4
Enrollment
68
Registered
2021-04-04
Start date
2021-04-21
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention 1: Intervention group: Corona treatment (1- Remedicivir: 200 mg on the first day and then 100 mg daily for 4 days
2- Dexamethasone: 8 mg daily
3- Enoxaparin 40 mg every 12 hours or Heparin 5000 units every 8 hours) + Padzahr tablets (made by NIAK with license number 0385-94-S): 2 pieces, after meals (three times a day). Intervention 2: Contr
3- Enoxaparin 40 mg every 12 hours or Heparin 5000 units every 8 hours).

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Probable diagnosis of COVID-19 based on national Iranian protocol

Exclusion criteria

Exclusion criteria: Late 5 days from the onset of symptoms Existence of comorbidity Pregnancy and lactation history of Allergy Complicated with bacterial infection

Design outcomes

Primary

MeasureTime frame
Fever reduction time. Timepoint: Time to start reducing fever after the intervention. Method of measurement: hour.;Fever intensity. Timepoint: All days of hospitalization. Method of measurement: C.;Blood oxygen saturation. Timepoint: All days after the intervention. Method of measurement: Pulse oximetry.

Secondary

MeasureTime frame
Duration of hospital stay. Timepoint: Patient discharge time. Method of measurement: day.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAssie Jokar

Mazandaran University of Medical Sciences

a.jokar@mazums.ac.ir+98 11 3324 3117

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026